| Autor: |
Pereira MN; Laboratory of Food, Drug & Cosmetics (LTMAC), School of Health Sciences, University of Brasília, 70910-900, Brasília, DF, Brazil., Ushirobira CY; Laboratory of Food, Drug & Cosmetics (LTMAC), School of Health Sciences, University of Brasília, 70910-900, Brasília, DF, Brazil., Cunha-Filho MS; Laboratory of Food, Drug & Cosmetics (LTMAC), School of Health Sciences, University of Brasília, 70910-900, Brasília, DF, Brazil., Gelfuso GM; Laboratory of Food, Drug & Cosmetics (LTMAC), School of Health Sciences, University of Brasília, 70910-900, Brasília, DF, Brazil., Gratieri T; Laboratory of Food, Drug & Cosmetics (LTMAC), School of Health Sciences, University of Brasília, 70910-900, Brasília, DF, Brazil. |
| Abstrakt: |
Alopecia is the partial or total reduction of hair in a specific area of the skin that affects millions of men and women worldwide. Most common approved treatments present inconvenient therapeutic regimes and serious adverse effects. In this scenario, nanoencapsulation has emerged as a relatively simple technology for improving the therapeutic outcome of this pathology, promoting a targeted drug delivery with enhanced local bioavailability, which could reduce the adverse effects. Herein, we present some recent studies involving the nanosystems developed for the pharmacological treatment of alopecia, highlighting how each system represents an improvement in relation to conventional drug products and the future perspectives of these new technologies in reaching the market. |
